Loading…

ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50

Half maximal inhibitory concentrations (IC 50 ) to the experimental drug ATI-2307 and complete inhibition (IC 90 ) of the common clinically used antifungal drug amphotericin B were determined by microbroth dilution assay for a collection of 69 clinical isolates of Cryptococcus neoformans from Uganda...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cellular and infection microbiology 2021-06, Vol.11, p.695240-695240
Main Authors: Gerlach, Elliot S., Altamirano, Sophie, Yoder, J. Marina, Luggya, Tony S., Akampurira, Andrew, Meya, David B., Boulware, David R., Rhein, Joshua, Nielsen, Kirsten
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Half maximal inhibitory concentrations (IC 50 ) to the experimental drug ATI-2307 and complete inhibition (IC 90 ) of the common clinically used antifungal drug amphotericin B were determined by microbroth dilution assay for a collection of 69 clinical isolates of Cryptococcus neoformans from Uganda that had high fluconazole IC 50 values. The majority of the clinical isolates tested had fluconazole IC 50 at or above 8 µg/mL, but were susceptible to both amphotericin B (IC 90 ≤1 μg/mL) and ATI-2307 (IC50 ≤0.0312 µg/mL). No correlation between increased fluconazole minimum inhibitory concentration (MIC) and ATI-2307 or amphotericin B MIC was observed, suggesting that the cellular changes impacting fluconazole susceptibility did not impact the effectiveness of ATI-2307. Our results suggest that ATI-2307 is a promising new antifungal drug for use in the context of high fluconazole or other antifungal drug MICs and/or in combination drug therapy regimens.
ISSN:2235-2988
2235-2988
DOI:10.3389/fcimb.2021.695240